The U.S. Food and Drug Administration (FDA) has granted emergency use authorizations (EUAs) to two additional COVID-19 at-home tests: the Siemens' CliniTest Rapid COVID-19 Antigen Self-Test and the SD Biosensor test distributed by Roche.
Both tests received the EUAs after being evaluated through the Biden administration's new accelerated pathway to support the FDA's review of tests. The program also provides an opportunity for large-scale manufacturing that the U.S. Department of Health and Human Services announced earlier in 2021.
The timely authorizations are due to a collaboration between the FDA and the National Institutes of Health Rapid Acceleration of Diagnostics Technology (RADx) program. Combined, it is estimated the companies can produce tens of millions of tests per month for use in the U.S., according to a press release by the FDA.
